AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02211378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observer
Description: Trainees are in the role of observers (not actively participating in simulation scenario) during first 2 simulation sessions, then placed in the role in the 'hotseat' actively participating during the third simulation session.
Study NCT02211378 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hotseat
Description: Trainees in the hotseat group are placed in the 'hotseat' to actively participate and manage the simulated medical crises in the simulation scenarios.
Study NCT02227784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally
Study NCT02227784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally
Study NCT02227784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally
Study NCT02227784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Administered orally
Study NCT02227784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT02227784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT00873717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dentary
Description: cleaning-up of oral cavity, with trimestrial dental and oral check-up with counseling for appropriate care (if needed).
Study NCT00873717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: control of the administration of dietary prescriptions, incitement to eat.
Study NCT00873717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dentary + Nutrition
Description: trimestrial follow-up of patients and counseling for appropriate care (if needed), in order to restore a minimum masticatory function, associated with particular focus on the realization of daily oral wash.~associated with control of the administration of dietary prescriptions, incitement to eat.
Study NCT00643019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFE Behavioral Intervention
Description: Group cognitive behavioral intervention sessions
Study NCT00643019 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Individual Sexually Transmitted Infection Risk Reduction Counseling
Study NCT03940196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100L(O)
Description: Patients receive continuous TTFields treatment using the NovoTTF-100L(O) device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the abdomen/pelvis. The treatment enables the patient to maintain regular daily routine.
Study NCT03940196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m\^2 intravenous infusion will be administered weekly for 8 weeks and then on Days 1, 8 and 15 of each subsequent 28-day cycle.
Study NCT03940196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m\^2 intravenous infusion will be administered weekly for 8 weeks and then on Days 1, 8 and 15 of each subsequent 28-day cycle.
Study NCT03153046 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: prebiotics
Description: Bimuno (BGOS): The active supplement of the food supplement (Bimuno) used in this study is called galacto-oliogosaccharides (Bimuno®, BGOS). BGOS is a compound metabolised by specific bifidobacteria, which are beneficial bacteria, in our colon. Bimuno (2.3 calories) is composed by the following ingredients per gram of Bimuno: 0.96g dry matter; \<01g Fat; \<0.06g Protein; 0.821g GOS; 0.119g Lactose; 0.0331g Glucose and 0.0029g Galactose. Bimuno is tasteless. Bimuno will be supplied in coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.
Study NCT03153046 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin is a polysaccharide in powder form, which grows most bacteria in the gut, and not specifically the beneficial bifidobacteria. The placebo will also be provided in daily coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink. This placebo has been used in previous studies, in which Bimuno was used as the active intervention. The placebo will be similar in taste and colour to the active intervention.
Study NCT00196105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 6 mm Nitinol Zilver Stent
Study NCT00196105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10 mm Nitinol Zilver Stent
Study NCT00196105 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 10 mm Stainless Steel Wallstent
Study NCT02587767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 577-MPL
Description: All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm LaserSystem) in 577-MPL arm. The individual power for the patient was titrated at a normal area of near the affected area in micropulse model.The power titration was started at 700 milliwatt(mW) and then gradually increased until a just visible burn was seen. When this threshold was reached, the power was reduced by 50%, using a 100-μm spot diameter and a 200-ms duration with 5 % duty cycle.
Study NCT02587767 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD-PDT
Description: 5 minutes after the start of the half-dose verteporfin infusion, the PDT treatment will been performed in HD-PDT arm. The treatment is performed with standard fluency (50 J/cm2), a PDT laser wavelength of 689 nm, and a standard treatment duration of 83 seconds.
Study NCT01005576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan
Description: Days -50 to -21: Hydroxyurea 30mg/kg po Day -22: Alemtuzumab 3mg IV Day -21: Alemtuzumab 10mg IV Day -20: Alemtuzumab 15mg IV Day -19: Alemtuzumab 20mg IV Day -8: Fludarabine 30mg/m2 IV Day -7: Fludarabine 30mg/m2 IV Day -6: Fludarabine 30mg/m2 IV Day -5: Fludarabine 30mg/m2 IV Day -4: Fludarabine 30mg/m2 IV Day -4: Thiotepa 8mg/kg IV Day -3: Melphalan 140mg/m2 IV Day 0: Stem cell infusion
Study NCT01893697 — intervention group
Intervention type: OTHER
Intervention: HRCT scan in a specific postural position
Description: HRCT Scan taken in supine and lateral position
Study NCT00784719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Ophthalmic topical solution, low dose, dosed at least once/day, 8 weeks
Study NCT00784719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Ophthalmic topical solution, medium dose, dosed at least once/day, 8 weeks
Study NCT00784719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Ophthalmic topical solution, intermediate dose, dosed at least once/day, 8 weeks
Study NCT00784719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Ophthalmic topical solution, high dose, dosed at least once/day, 8 weeks
Study NCT00784719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Ophthalmic topical solution, 0.05%, dosed at least once/day, 8 weeks
Study NCT00784719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CP-690,550 Vehicle
Description: Ophthalmic topical solution, dosed at least once/day, 8 weeks
Study NCT04157088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (Nubeqa, BAY1841788)
Description: 600mg, twice daily
Study NCT04157088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160mg, once daily
Study NCT03509181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-Change
Description: smartphone delivered word-sentence association task that encourages a healthier interpretive style
Study NCT03509181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Tracking
Description: smartphone delivered self-monitoring of anxiety and depression symptoms
Study NCT03509181 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom Tracking
Description: smartphone delivered self-monitoring of anxiety and depression symptoms
Study NCT05701254 — intervention group
Intervention type: PROCEDURE
Intervention: Transilial bone biopsy
Description: The transiliac bone biopsy will be performed on each subject under local anesthesia, and conscious sedation. From one skin incision located \~2cm posterior and inferior to the anterior-superior pelvic spine on one side of the pelvis, the investigators will obtain two iliac bone specimens, each 7.5 mm in diameter, cylindrical in shape, and including both inner and outer cortices and the intervening trabecular bone.
Study NCT02288819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weight monitoring
Description: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days
Study NCT02288819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loop diuretic downtitration
Description: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.~In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.~In case of a total daily maintenance dose >40 mg furosemide OR >1 mg bumetanide OR >20 mg torsemide, the loop diuretic dose is halved.
Study NCT03962621 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Fotona 4D 1064 nm laser
Description: The 1064 nm laser can penetrate deep into the skin to explode pigment particles, destroy blood vessels and heat the dermal collagen by targeting melanin and haemoglobin.(1) Frac3®: 30-35 J/cm2, 1.6 ms pulse width, 4mm spot size, unilaterally accumulated 2000 shots; and (2) PIANO®: 160 J/cm2, 5s pulse width, spot size 9mm, unilaterally accumulated 20000 shots, to increase and maintain facial skin temperature to 39-40oC.
Study NCT03962621 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fotona 4D 1064 nm laser
Description: The 1064 nm laser can penetrate deep into the skin to explode pigment particles, destroy blood vessels and heat the dermal collagen by targeting melanin and haemoglobin.(1) Frac3®: 30-35 J/cm2, 1.6 ms pulse width, 4mm spot size, unilaterally accumulated 2000 shots; and (2) PIANO®: 160 J/cm2, 5s pulse width, spot size 9mm, unilaterally accumulated 20000 shots, to increase and maintain facial skin temperature to 39-40oC.
Study NCT04737720 — intervention group
Intervention type: DRUG
Intervention: Recombinant LCAT
Description: iv infusion
Study NCT03962621 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Fotona 4D 2940 nm laser
Description: Er:YAG 2940nm have been considered as a good treatment of facial aging, especially in wrinkles.(1) Smooth®: 9-10 J/cm2, 7mm spot size, which is sequentially delivered to upper and lower labial mucosa and buccal mucosa to unilaterally accumulate 5000 shots; (2) SupErficial™: 0.5-1.0 J/cm2, 7mm spot size, a single pass
Study NCT03962621 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fotona 4D 2940 nm laser
Description: Er:YAG 2940nm have been considered as a good treatment of facial aging, especially in wrinkles.(1) Smooth®: 9-10 J/cm2, 7mm spot size, which is sequentially delivered to upper and lower labial mucosa and buccal mucosa to unilaterally accumulate 5000 shots; (2) SupErficial™: 0.5-1.0 J/cm2, 7mm spot size, a single pass
Study NCT02902042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Dose determined in phase I. Start dose: 450 mg qd
Study NCT02902042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Dose determined in phase I. Start dose: 45 mg bid
Study NCT02902042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Dose determined in phase I. Start dose: 200 mg q3w
Study NCT02902042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab alone
Description: 200 mg q3w
Study NCT03666247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthMindr Application
Description: From baseline to 3-month post-test, participants in the intervention arm are granted access and instructed to interact regularly with the HealthMindr messaging platform. The HealthMindr messaging platform delivers messages relevant to both general audiences of sexually-active MSM, as well as messages relevant only to specific subgroups of HIV-positive men, and currently higher and lower risk HIV-negative men. Answers provided during the assessments determine which subset of messages are delivered to app users, with information such as HIV status, changes in self-reported risk behaviors, or other factors that influence the relevance of any given message. The HealthMindr application also offers free condoms, lube, and a HIV and STI testing kits.
Study NCT03666247 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist
Description: Participants assigned to the waitlist-control arm will be given a welcome sheet orienting them to the study. The message they view will include the same resources links provided to the intervention arm. The information will cover the importance of testing, links to an online mapping tool about the HIV epidemic in the United States (AIDSVu) and resources to locate HIV testing services and prevention information in their area. No information recommending frequency of testing will be given in the welcome greeting.
Study NCT00596050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine and midazolam
Description: ketamine 1 mg/kg/dose, midazolam 0.05 mg/kg/dose max 2 mg
Study NCT00596050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etomidate, fentanyl, and lidocaine
Description: etomidate 0.2 mg/kg/dose, fentanyl 1 microgram/kg/dose, lidocaine 0.5 mg/kg/dose
Study NCT04663243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thinking healthy Program sessions designed for antenatal period
Description: Low line psychosocial intervention based on the principles of Cognitive Behavior Therapy (CBT), designed for non-specialist will be applied for expectant women experiencing depression during mid to late-pregnancy. It uses the core principles and strategies of the Thinking Healthy Program (THP). Four core sessions and two booster sessions will be applied, designed for antenatal period to prevent antenatal and post partum depression.
Study NCT03893955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-927
Description: Intravenous (IV) Infusion
Study NCT04066881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48)
Description: 1. DNA-HIV-PT123 HIV vaccine includes three DNA plasmids that encode clade C ZM96 Gag, clade C ZM96 Env, and CN54 Pol-Nef.~2. AIDSVAX® B/E is a bivalent HIV gp120 glycoprotein encompassing both subtype B (MN) and subtype E (A244) proteins that are adsorbed onto 600mcg of aluminum hydroxide gel suspension as adjuvant.
Study NCT04066881 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48)
Description: 1. DNA-HIV-PT123 HIV vaccine includes three DNA plasmids that encode clade C ZM96 Gag, clade C ZM96 Env, and CN54 Pol-Nef.~2. AIDSVAX® B/E is a bivalent HIV gp120 glycoprotein encompassing both subtype B (MN) and subtype E (A244) proteins that are adsorbed onto 600mcg of aluminum hydroxide gel suspension as adjuvant.
Study NCT04066881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48)
Description: 1. DNA-HIV-PT123 (see above)~2. CN54gp140+MPLA-L. Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity.~3. MVA-CMDR (Modified Vaccinia Ankara-Chiang Mai Double Recombinant) is a non-replicating, highly attenuated strain of Vaccina virus that has been genetically engineered to express the HIV-1 genes envgp160 CM235 Subtype E and gag and pol CM240 Subtype A (integrase-deleted and reverse transcriptase non-functional).
Study NCT03893955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-368
Description: Intravenous (IV) Infusion
Study NCT03893955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous (IV) Infusion
Study NCT03893955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous (IV) Infusion
Study NCT03893955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Intravenous (IV) Infusion
Study NCT01830933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BreastCARE
Description: Physician Report. At the time of an individual participant's visit to her primary care physician and her completion of the assessment tool, her physician will receive a physician report. The physician report is designed to facilitate communication about breast cancer risk during the primary care visit and to provide tailored risk reduction recommendations.
Study NCT01681238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protocol group 2
Description: ensure SpO2≥ 92%, MAP 65-100 mmHg, HR \<100 bpm, Hb> 8mg/dL and temperature ≥ 36℃, the patients were then administrated a 200 ml colloid as a fluid challenge. The fluid challenge repeat until the SV failed to increase by a factor of 10%. If at this stage the DO2I can not be greater than 600 mL/m2, then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 20 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 120 beats per minute or shows signs of cardiac ischemia. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL
Study NCT01681238 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Protocol group 1
Description: The goal of this protocol is to ensure MAP> 65 mmHg, CVP 8-12 cmH2O. If meet the above requirements, do nothing, re-evaluate after 5min. If CVP \<8 cmH2O, the patient will receive an additional 200ml colloid .If MAP beyond the scope of 65-100 mmHg, vasoactive agents will be administrated until achieve the goal. If 25mL/kg colloid given before goal is achieved, fluid challenges will then be performed with 200mL boluses of Ringer's lactate solution. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL
Study NCT03822260 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bezmialem VAkif Unv. Ethical board
Description: If ıs any trials not convenient to Helsinki Agrement about Human research rules
Study NCT00201019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician-pharmacist collaborative intervention
Description: Participants receive assessment and medication and lifestyle recommendations from a clinical pharmacist.
Study NCT03337620 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tx360
Description: Tx360 used to deliver active and placebo drug interventions to SPG.
Study NCT03337620 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Tx360
Description: Tx360 used to deliver active and placebo drug interventions to SPG.
Study NCT05323747 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Assessment of rectal dosimetry change from pre-insertion to post-insertion in subjects with prostate cancer who have undergone radiotherapy with a hydrogel spacer.
Study NCT02105233 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: brain mimicking fluid
Description: filled into the operation cavity during surgery for glioblastoma
Study NCT00914134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa infusion
Description: Naso-duodenal infusion line is inserted in fluoroscopy control. Levodopa infusion is then tested approximately 5 days. If patient responds favorably to the treatment, PEG-infusion line is inserted in gastroscopy control and patient is followed in hospital for 2 to 4 days to ensure stability of the infusion line. The dosage is individually adjusted, starting dose is estimated from earlier oral levodopa dose.
Study NCT04346160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Schirmer Test I
Description: Collection of tear fluid
Study NCT00908414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589337 40 mg
Description: Participants will receive TMC589337 40 mg in Session Ia of Panel 1.
Study NCT00908414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589337 100 mg
Description: Participants will receive TMC589337 100 mg in Session IIa of Panel 1.
Study NCT00908414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC589337 200 mg
Description: Participants will receive TMC589337 200 mg in Session IIIa of Panel 1.
Study NCT04066881 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vaccine Group C: Saline placebo (weeks 0,4,24,48)
Description: Sodium Chloride (NaCl) for injection, 0.9%
Study NCT04066881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control PrEP:TDF/FTC once daily (weeks 0-26)
Description: Each tablet of Truvada contains 245mg of tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.